Dr Stipo Jurcevic


2022

microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells
Mortoglou, M., Miralles, F., Arisan, E.D., Dart, A., Jurcevic, S., Lange, S. and Uysal Onganer, P. 2022. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences. 23 (3) 1275. https://doi.org/10.3390/ijms23031275

2018

Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1)
Lee, M.H., Thomas, J.L., Liao, C.L., Jurcevic, S., Crnogorac-Jurcevic, T. and Lin, H.Y. 2018. Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1). Separation and Purification Technology. 192, pp. 213-219. https://doi.org/10.1016/j.seppur.2017.09.071

2017

Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma
Jurcevic, S., Lee, M-H., Thomas, J.L., Liao, C-L., Crnogorac-Jurcevic, T. and Lin, H-Y. 2017. Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma. Microchimica Acta. 184 (6), p. 1773–1780. https://doi.org/10.1007/s00604-017-2169-4

2015

The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Jurcevic, S., Humfrey, C., Uddin, M., Warrington, S., Larsson, B. and Keen, C. 2015. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol. . 80 (6), pp. 1324-36. https://doi.org/10.1111/bcp.12724

2015

The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski, J.A., Zhou, C., Winters, K.J., Lachno, D.R., Howard, J., Payne, C.D., Mant, T., Jurcevic, S. and Frelinger, A.L. 2015. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 26 (5), pp. 474-479. https://doi.org/10.3109/09537104.2014.940887

2008

An Antibody Combination That Targets Activated T Cells Extends Graft Survival in Sensitized Recipients
Jurcevic, S. 2008. An Antibody Combination That Targets Activated T Cells Extends Graft Survival in Sensitized Recipients. American Journal of Transplantation. 8 (11), pp. 2272-2282. https://doi.org/10.1111/j.1600-6143.2008.02393.x

2006

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation
Jurcevic, S., Braselmann, S., Taylor, V., Zhao, H., Wang, S. and Masuda, E.S. 2006. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. Journal of Pharmacology and Experimental Therapeutics. 319 (3), pp. 998-1008 109058/3152109. https://doi.org/10.1124/jpet.106.109058

2017

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Simha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology. 57 (2), pp. 194-210. https://doi.org/10.1002/jcph.794

2016

Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans
Jurcevic, S., Juif, P.E., Hamid, C., Greenlaw, R., D'Ambrosio, D. and Dingemanse, J. 2016. Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans. Drug Design, Development and Therapy. 11, pp. 123-131. https://doi.org/10.2147/DDDT.S120399

2014

FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells
Rani, A., Greenlaw, R., Runglall, M., Jurcevic, S. and John, S. 2014. FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells. PLoS ONE. 9 (2), p. e90370. https://doi.org/10.1371/journal.pone.0090370

2014

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation
Jakubowski, J.A., Zhou, C., Jurcevic, S., Winters, K.J., Lachno, D.R., Frelinger, A.L., Gupta, N., Howard, J., Payne, C.D. and Mant, T. 2014. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thrombosis Research. 133 (2), pp. 190-5. https://doi.org/10.1016/j.thromres.2013.12.008


Usage Statistics
905 total views of outputs
1313 total downloads of outputs
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.